

## 顎口腔外科学分野

1. Ohsako T, Shimamoto H, Tomioka H, Hirai H, Kuroshima T, Mochizuki Y, Kugimoto T, Tsushima F, Nakamura S, Kurabayashi T, **Harada H**. Detection of extraoral primary cancers by positron emission tomography/computed tomography in patients with oral squamous cell carcinoma. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 129(3):272-276, 2020.
2. Yokokawa M, Morita KI, Oikawa Y, Kayamori K, Sakamoto K, Ikeda T, **Harada H**. Co-expression of EGFR and MET has a synergistic effect on the prognosis of patients with oral squamous cell carcinoma. *J Oral Pathol Med*. 49(3):235-242, 2020.
3. Nojima H, Homma H, Onozato Y, Kaida A, **Harada H**, Miura M. Differential properties of mitosis-associated events following CHK1 and WEE1 inhibitor treatments in human tongue carcinoma cells. *Exp Cell Res*. 386(2):111720, 2020.
4. Takagawa Y, Gen Y, Muramatsu T, Tanimoto K, Inoue J, **Harada H**, Inazawa J. miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway. *Mol Ther*. 28(6):1494-1505, 2020.
5. Kagifuku Y, Tohara H, Wakasugi Y, Susa C, Nakane A, Toyoshima M, Nakakuki K, Kabasawa Y, **Harada H**, Minakuchi S. What Factors Affect Changes in Body Composition and Swallowing Function in Patients Hospitalized for Oral Cancer Surgery? *Clin Interv Aging*. 15:1-7, 2020.
6. Kinoshita N, Sasaki Y, Marukawa E, Hirose R, Sawada SI, **Harada H**, Akiyoshi K. Crosslinked nanogel-based porous hydrogel as a functional scaffold for tongue muscle regeneration. *J Biomater Sci Polym Ed*. 31(10):1254-1271, 2020.
7. Kaneko A, Marukawa E, **Harada H**. Hydroxyapatite Nanoparticles as Injectable Bone Substitute Material in a Vertical Bone Augmentation Model. *In Vivo*. 34(3):1053-1061, 2020.
8. Takei J, Kaneko MK, Ohishi T, Kawada M, **Harada H**, Kato Y. H 2 Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts. *Exp Ther Med*. 20(2):846-853, 2020.
9. Hirai H, Ohsako T, Kugimoto T, Tomioka H, Michi Y, Kayamori K, Yoda T, Miura M, Yoshimura R, **Harada H**. Comparison of 50- and 66-Gy total irradiation doses for postoperative cervical treatment of patients with oral squamous cell carcinoma. *Oral Oncol*. 107:104708, 2020.
10. Takei J, Kaneko MK, Ohishi T, Kawada M, **Harada H**, Kato Y. A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent

cytotoxicity. *Oncol Lett.* 19(4):2809-2816, 2020

11. Takei J, Ohishi T, Kaneko MK, **Harada H**, Kawada M, Kato Y. A defucosylated anti-PD-L1 monoclonal antibody 13-mG 2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. *Biochem Biophys Rep.* 24:100801, 2020.
12. Kashima Y, Nishii N, Tachinami H, Furusawa E, Nagai S, **Harada H**, Azuma M. Orthotopic tongue squamous cell carcinoma (SCC) model exhibiting a different tumor-infiltrating T-cell status with margin-restricted CD8 + T cells and regulatory T cell-dominance, compared to skin SCC. *Biochem Biophys Res Commun.* 526(1):218-224, 2020.
13. Hosono H, Takei J, Ohishi T, Sano M, Asano T, Sayama Y, Nakamura T, Yanaka M, Kawada M, **Harada H**, Kaneko MK, Kato Y. Anti EGFR monoclonal antibody 134 mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. *Int J Mol Med.* 10, 2020.
14. Shimamoto H, Hirota Y, Kashima Y, Kinoshita N, Yokokawa M, Ikeda T, **Harada H**. Granulocyte colony-stimulating factor-producing squamous cell carcinoma of the tongue exhibiting characteristic fluorine-18 deoxyglucose accumulation on positron emission tomography-computed tomography: A case report. *World J Clin Cases.* 8(9):1666-1673, 2020.
15. Fukuda S, Akiyama M, **Harada H**, Nakahama KI. Effect of gap junction-mediated intercellular communication on TGF- $\beta$  induced epithelial-to-mesenchymal transition. *Biochem Biophys Res Commun.* 508(3): 928-933, 2019.
16. Takada K, Kuroshima T, Shimamoto H, Ohsako T, Kayamori K, Ikeda T, **Harada H**. Metastasis of lower gingival squamous cell carcinoma to buccinator lymph node: case report and review of the literature. *World J Surg Oncol.* 17(1): 13, 2019.
17. Sato K, Shimamoto H, Mochizuki Y, Hirai H, Tomioka H, Shimizu R, Marukawa E, Fukayama H, Yoshimura R, Ishida H, **Harada H**. Treatment of oral cancers during pregnancy: a case-based discussion. *J Otolaryngol Head Neck Surg.* 48(1): 9, 2019.
18. Furusawa Y, Yamada S, Itai S, Namamura T, Yanaka M, Sano M, **Harada H**, Fukui M, Kaneko M, Kato Y. PMab-219: A monoclonal antibody for the immunohistochemical analysis of horse podoplanin. *Biochem Biophys Rep.* 18: 100616, 2019.
19. Furusawa Y, Yamada S, Itai S, Sano M, Nakamura T, Yanaka M, Fukui M, **Harada H**, Mizuno T, Sakai Y, Takasu M, Kaneko M, Kato Y. P-Mab-210: A Monoclonal Antibody Against Pig Podoplanin. *Monoclon Antib Immunodiagn Immunother.* 38(1): 30-36, 2019.
20. Tachinami H, Nishii N, Xia Y, Kashima Y, Ohno T, Nagai S, Li L, Lau W, Tomihara

- K, Noguchi M, Azuma M. Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade. *Oral Oncol.* 91: 21-28, 2019.
21. Tomioka H, Mochizuki Y, Ohsako T, Hirai H, Shimamoto H, **Harada H**. Buccinator and mandibular node metastases in oral squamous cell carcinoma. *J Oral Maxillofac Surg.* 77(4): 867-873, 2019.
  22. Kaneko MK, Furusawa Y, Sano M, Itai S, Takei J, **Harada H**, Fukui M, Yamada S, Kato Y. Epitope mapping of the antihorse podoplanin monoclonal antibody PMab-202. *Monoclon Antib Immunodiagn Immunother.* 38(2): 79-84, 2019.
  23. Furusawa Y, Kaneko MK, Nakamura T, Itai S, Fukui M, **Harada H**, Yamada S, Kato Y. Establishment of a monoclonal antibody PMab-231 for tiger podoplanin. *Monoclon Antib Immunodiagn Immunother.* 38(2): 89-95, 2019.
  24. Yamada S, Kaneko MK, Furusawa Y, Itai S, Sano M, Nakamura T, Yanaka M, Handa S, Hisamatsu K, Nakamura Y, Koyanagi M, Fukui M, **Harada H**, Kato Y. Anti-Bovine Podoplanin Monoclonal Antibody PMab-44 Detects Goat Podoplanin in Immunohistochemistry. *Monoclon Antib Immunodiagn Immunother.* 38(2): 96-99, 2019.
  25. Okuyama K, Fukushima H, Naruse T, Yanamoto S, Tsuchihashi H, Umeda M. CD44 Variant 6 Expression and Tumor Budding in the Medullary Invasion Front of Mandibular Gingival Squamous Cell Carcinoma Are Predictive Factors for Cervical Lymph Node Metastasis. *Pathol Oncol Res.* 25(2):603-609, 2019.
  26. Furusawa Y, Yamada S, Itai S, Nakamura T, Takei J, Sano M, **Harada H**, Fukui M, Kaneko MK, Kato Y. Establishment of a monoclonal antibody PMab-233 for immunohistochemical analysis against Tasmanian devil podoplanin. *Biochem Biophys Rep.* 18:100631, 2019.
  27. Kato Y, Furusawa Y, Yamada S, Itai S, Takei J, Sano M, Kaneko MK. Establishment of a monoclonal antibody PMab-225 against alpaca podoplanin for immunohistochemical analyses. *Biochem Biophys Rep.* 18: 100633, 2019.
  28. Oshibe N, Marukawa E, Yoda T, **Harada H**. Degradation and interaction with bone of magnesium alloy WE43 implants: A long-term follow-up in vivo rat tibia study. *J Biomater Appl.* 33(9): 1157-1167, 2019.
  29. Furusawa Y, Takei J, Sayama Y, Yamada S, Kaneko MK, Kato Y. Development of an anti-bear podoplanin monoclonal antibody PMab-247 for immunohistochemical analysis. *Biochem Biophys Rep.* 18: 100644, 2019.
  30. Minegishi S, Ohtani S, Noritake K, Funakoshi T, Ishii N, Utsuno H, Sakuma A, Saitoh H, Yamaguchi S, Marukawa E, **Harada H**, Uemura K, Sakurada K.

Preparation of dentin standard samples for age estimation based on increased aspartic acid racemization rate by heating. *Leg Med (Tokyo)*. 38: 25-31, 2019.

31. Suzuki N, Kuribayashi A, Sakamoto K, Sakamoto J, Nakamura S, Watanabe H, **Harada H**, Kurabayashi T. Diagnostic abilities of 3T MRI for assessing mandibular invasion of squamous cell carcinoma in the oral cavity: comparison with 64-row multidetector CT. *Dentomaxillofac Radiol*. 48(4): 20180311, 2019.
32. Kato Y, Furusawa Y, Itai S, Takei J, Nakamura T, Sano M, **Harada H**, Yamada S, Kaneko MK. Establishment of an Anticetacean Podoplanin Monoclonal Antibody PMab-237 for Immunohistochemical Analysis. *Monoclon Antib Immunodiagn Immunother*. 38(3): 108-113, 2019.
33. Kato Y, Itai S, Yamada S, Suzuki H, Kaneko MK. Epitope Mapping of Anti-Diacylglycerol Kinase  $\zeta$  Monoclonal Antibody for the Detection of T Cells by Immunohistochemical Analyses. *Monoclon Antib Immunodiagn Immunother*. 38(3): 124-128, 2019.
34. Takei J, Itai S, Furusawa Y, Yamada S, Nakamura T, Sano M, **Harada H**, Fukui M, Kaneko MK, Kato Y. Epitope mapping of anti-tiger podoplanin monoclonal antibody PMab-231. *Monoclon Antib Immunodiagn Immunother*. 38(3): 129-132, 2019.
35. Komiya R, Wada T, Tsushima F, Sakamoto K, Ikeda T, Yamaguchi A, **Harada H**, Uo M. Quantitation and distribution of metallic elements in sequestra of medication-related osteonecrosis of jaw (MRONJ) using inductively coupled plasma atomic emission spectroscopy and synchrotron radiation X-ray fluorescence analysis. *J Bone Miner Metab*. 37(4): 676-684, 2019.
36. Furusawa Y, Yamada S, Nakamura T, Sano M, Sayama Y, Itai S, Takei J, **Harada H**, Fukui M, Kaneko MK, Kato Y. PMab-235: A monoclonal antibody for immunohistochemical analysis against goat podoplanin. *Heliyon*. 5(7): e02063, 2019.
37. Kato Y, Ohishi T, Yamada S, Itai S, Takei J, Sano M, Nakamura T, **Harada H**, Kawada M, Kaneko MK. Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-41-Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer. *Monoclon Antib Immunodiagn Immunother*. 38(4): 157-161, 2019.
38. Takei J, Furusawa Y, Yamada S, Nakamura T, Sayama Y, Sano M, Konnai S, Kobayashi A, **Harada H**, Kaneko MK, Kato Y. PMab-247 Detects Bear Podoplanin in Immunohistochemical Analysis. *Monoclon Antib Immunodiagn Immunother*. 38(4): 171-174, 2019.
39. Okuyama K, Naruse T, Yutori H, Yanamoto S, Umeda M. Oral surgery in patients with antiphospholipid syndrome. *J Oral Sci*. 61(3): 386-390, 2019.

40. Takei J, Itai S, **Harada H**, Furusawa Y, Miwa T, Fukui M, Nakamura T, Sano M, Sayama Y, Yanaka M, Handa S, Hisamatsu K, Nakamura Y, Yamada S, Kaneko MK, Kato Y. Characterization of Anti-Goat Podoplanin Monoclonal Antibody PMab-235 Using Immunohistochemistry Against Goat Tissues. *Monoclon Antib Immunodiagn Immunother*. 38(5): 213-219, 2019.
41. Kato Y, Takei J, Furusawa Y, Sayama Y, Sano M, Konnai S, Kobayashi A, **Harada H**, Takahashi M, Suzuki H, Yamada S, Kaneko MK. Epitope Mapping of Anti-Bear Podoplanin Monoclonal Antibody PMab-247. *Monoclon Antib Immunodiagn Immunother*. 38(5): 230-233, 2019.
42. Takei J, Yamada S, Konnai S, Ishinazaka T, Shimozuru M, Kaneko MK, Kato Y. PMab-241 Specifically Detects Bear Podoplanin of Lymphatic endothelial cells in the Lung of Brown Bear. *Monoclon Antib Immunodiagn Immunother*. 38(6): 282–284, 2019.
43. Oikawa Y, Michi Y, Tsushima F, Tomioka H, Mochizuki Y, Kugimoto T, Osako T, Nojima H, Yokokawa M, Kashima Y, **Harada H**. Management of retropharyngeal lymph node metastasis in oral cancer. *Oral Oncol*. 99:104471, 2019.
44. Homma H, Nojima H, Kaida A, Miura M. Induction of endomitosis-like event in HeLa cells following CHK1 inhibitor treatment. *Biochem Biophys Res Commun*. 520(2):492-497, 2019.
45. Kaneko MK, Yamada S, Itai S, Chang YW, Nakamura T, Yanaka M, **Harada H**, Suzuki H, Kato Y. Elucidation of the T Mab-6 Monoclonal Antibody Epitope against Telomerase Reverse Transcriptase. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 38(3):101-103, 2019.
46. Ishida S, Kayamori K, Sakamoto K, Yukimori A, Kugimoto T, **Harada H**, Ikeda T. Alpha-L-fucosidase-1 is a diagnostic marker that distinguishes mucoepidermoid carcinoma from squamous cell carcinoma. *Pathology International*. 69; 76-85, 2019.
47. Jiaranuchart S, Kaida A, Onozato Y, **Harada H**, Miura M. DNA damage response following X-irradiation in oral cancer cell lines HSC3 and HSC4. *Archives of oral biology*. 90; 1-8, 2018.
48. Furusawa W, Yamada S, Itai S, Nakamura T, Fukui M, **Harada H**, Kaneko MK, Kato Y. Elucidation of critical epitope of anti-rat podoplanin monoclonal antibody PMab-2. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 37(4):188-193, 2018.
49. Itai S, Yamada S, Kaneko M, Sano M, Nakamura T, Yanaka M, Handa S, Hisamatsu K, Nakamura Y, Furusawa Y, Fukui M, Ohishi T, Kawada M, **Harada H**, Kato Y. Podocalyxin is crucial for the growth of oral squamous cell carcinoma cell line HSC-

2. *Biochemistry and Biophysics Reports*.15; 93-96, 2018.

50. Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, Kawada M, **Harada H**, Kato Y. Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma. *Oncotarget*. 9(32); 22480-22497, 2018.
51. Kaneko MK, Yamada S, Itai S, Furusawa Y, Nakamura T, Yanaka M, Honda S, Hisamitsu K, Nakamura Y, Fukui M, **Harada H**, Kato Y. Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6. *Biochemistry and Biophysics Reports*. 15: 76-80, 2018.
52. Matsui T, Okada T, Kawada K, Okuda M, Ogo T, Nakajima Y, Kume Y, Ryotokuji T, Hoshino A, Tokairin Y, Michi Y, **Harada H**, Nakajima Y, Kawano T. Detection of second primary malignancies of the esophagus and hypopharynx in oral squamous cell carcinoma patients. *Laryngoscope Investig Otolaryngol*. 3(4):263-267, 2018.
53. Yamada I, Yoshino N, Hikishima K, Sakamoto J, Yokokawa M, Oikawa Y, **Harada H**, Kurabayashi T, Saida Y, Tateishi U, Yukimori A, Izumo T, Asahina S. Oral carcinoma: clinical evaluation using diffusion kurtosis imaging and its correlation with histopathologic findings. *Magnetic Resonance Imaging*. 51; 69-78, 2018.
54. Yamaga E, Toriihara A, Nakamura S, Asai S, Fujioka T, Yoshimura R, Michi Y, **Harada H**, Tateishi U. Clinical usefulness of 2-deoxy-2-[18F] fluoro-D-glucose-positron emission tomography/computed tomography for assessing early oral squamous cell carcinoma (cT1-2N0M0). *Japanese Journal of Clinical Oncology*. 48(7); 633-639, 2018.
55. Ohata Y, Kayamori K, Yukimori A, Sumikura K, Ohsako T, **Harada H**, Sakamoto K, Ikeda T. A lesion categorized between ghost cell odontogenic carcinoma and dentinogenic ghost cell tumor with CTNNB1 mutation. *Pathology International*. 68(5); 307-312, 2018.
56. Nishii N, Tachinami H, Kondo Y, Xia Y, Kashima Y, Ohno T, Nagai S, Li L, Lau W, **Harada H**, Azuma M. Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy. *Oncotarget*. 9(17); 13301-13312, 2018.
57. Yamada S, Kaneko MK, Itai S, Chang YW, Nakamura T, Yanaka M, Ogasawara S, Murata T, Uchida H, Tahara H, **Harada H**, Kato Y. Epitope Mapping of Monoclonal Antibody PMab-48 Against Dog Podoplanin. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 37(3); 162-165, 2018.
58. Sato M, **Harada H**, Nagata C, Suzuki K. A case of Ectomesenchymal

- Chondromyxoid Tumor on the tongue. *Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology*. 30; 134-137, 2018.
59. Ngamsom S, Nakamura S, Kabasawa Y, **Harada H**, Tohyama R, Kurabayashi T. Imaging findings of intraosseous traumatic neuroma of the mandible. *Oral Radiol*. 34: 257-261, 2018.
  60. Elbashti ME, Aswehlee AM, Hattori M, Sumita Y, Michi Y, Uzawa N, Yamaguchi S, **Harada H**, Taniguchi H. Surgeons' awareness of the considerations for prosthetic rehabilitation in maxillectomy patients. *日本顎顔面補綴学会誌*. 40(2); 12-20, 2017.
  61. Takemoto T, Kabasawa Y, Higuchi Y, Tabata Y, Aoki K, Tamura Y, **Harada H**. Combination of the RANKL-binding peptide W9 and bFGF induces ectopic bone regeneration in the rat calvarial defect model. *Dental. Oral and Craniofacial Research*. 4(3); 2-7, 2017.
  62. Yamada S, Itai S, Nakamura T, Chang YW, **Harada H**, Suzuki H, Kaneko MK, Kato Y. Establishment of H2Mab-119, an Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody, Against Pancreatic Cancer. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 36(6); 287-29, 2017.
  63. Itai S, Yamada S, Kaneko MK, Chang YW, **Harada H**, Kato Y. Establishment of EMab-134, a sensitive and specific anti-epidermal growth factor receptor monoclonal antibody for detecting squamous cell carcinoma cells of the oral cavity. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 36(6); 272-281, 2017.
  64. Itai S, Yamada S, Kaneko MK, **Harada H**, Kagawa Y, Konnai S, Kato Y. Expression of cat podoplanin in feline squamous cell carcinomas. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 36(6); 243-250, 2017.
  65. Ohata Y, Tatsuzawa A, Ohyama Y, Ichikawa A, Mochizuki Y, Ishibashi S, Itakura Y, Sakamoto K, Ikeda T, Kitagawa M, Yamamoto K. A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer. *Human Pathology*. 69; 129-139, 2017.
  66. Yamagata Y, Tomioka H, Sakamoto K, Sato K, **Harada H**, Ikeda T, Kayamori K. CD163-Positive Macrophages Within the Tumor Stroma Are Associated With Lymphangiogenesis and Lymph Node Metastasis in Oral Squamous Cell Carcinoma. *J Oral Maxillofac Surg*. 75(10); 2144-2153, 2017.
  67. Itai S, Fujii Y, Nakamura T, Chang YW, Yanaka M, Saidoh N, Handa S, Suzuki H, **Harada H**, Yamada S, Kaneko MK, Kato Y. Establishment of CMab-43, a Sensitive

- and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 36(5); 231-235, 2017.
68. Yamada S, Itai S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, **Harada H**, Kagawa Y, Ichii O, Konnai S, Kaneko MK, Kato Y. PMab-52: Specific and Sensitive Monoclonal Antibody Against Cat Podoplanin for Immunohistochemistry. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 36(5); 224-230, 2017.
69. Itai S, Yamada S, Kaneko MK, **Harada H**, Kato Y. Immunohistochemical Analysis Using Antipodocalyxin Monoclonal Antibody PcMab-47 Demonstrates Podocalyxin Expression in Oral Squamous Cell Carcinomas. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 36(5); 220-223, 2017.
70. Itai S, Kaneko MK, Fujii Y, Yamada S, Nakamura T, Yanaka M, Saidoh N, Handa S, Chang YW, Suzuki H, **Harada H**, Kato Y. Development of EMab-51, a Sensitive and Specific Anti-EGFR Monoclonal Antibody in Western Blot and Immunohistochemistry. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 36(5); 214-219, 2017.
71. Takahara N, Nakagawa S, Sumikura K, Kabasawa Y, Sakamoto I, **Harada H**. Association of TMJ pain according to magnetic resonance imaging findings in TMD patients. *J Oral Maxillofac Surg*. 75(9); 1848-1855, 2017.
72. Hirai H, Tomioka H, Mochizuki Y, Oikawa Y, Tsushima F, **Harada H**. Clinical Course of Oral Squamous Cell Carcinoma in Patients on Immunosuppressant and Glucocorticoid Therapy. *J Oral Maxillofac Surg*. 75(9); 1980-1986, 2017.
73. Itai S, Fujii Y, Kaneko MK, Yamada S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Takahashi M, Suzuki H, **Harada H**, Kato Y. H2Mab-77 is a sensitive and specific anti-HER2 monoclonal antibody against breast cancer. *Monoclonal Antibodies in Immunodiagnosis and Immunotherapy*. 36(4); 143-148, 2017.
74. Shimamoto H, Oikawa Y, Osako T, Hirai H, Mochizuki Y, Tanaka K, Tomioka H, **Harada H**. Neck failure after elective neck dissection in patients with oral squamous cell carcinoma. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 124(1); 32-36, 2017.
75. Mochizuki Y, **Harada H**, Shimamoto H, Tomioka H, Hirai H. Multiple Free Flap Reconstructions of Head and Neck Defects Due to Oral Cancer. *Plast Reconstr Surg Glob Open*. 13;5(6):e1337, 2017.
76. Takahara N, Kabasawa Y, Sato M, Tetsumura A, Kurabayashi T, Omura K. MRI changes in the temporomandibular joint following mandibular setback surgery using sagittal split ramus osteotomy with rigid fixation. *Cranio*. 35: 38-45, 2017.



77. Yukimori A, Oikawa Y, Morita K, Nguyen CT, **Harada H**, Yamaguchi S, Kayamori K, Yamaguchi A, Ikeda T, Sakamoto K. Genetic basis of calcifying cystic odontogenic tumors. *PLoS ONE*. 12(6); e0180224, 2017.
78. Onozato Y, Kaida A, **Harada H**, Miura M. Radiosensitivity of quiescent and proliferating cells grown as multicellular tumor spheroids. *Cancer Science*. 108; 704-712, 2017.
79. Nguyen CT, Okamura T, Morita K, Yamaguchi S, **Harada H**, Miki Y, Izumo T, Kayamori K, Yamaguchi A, Sakamoto K. LAMC2 is a predictive marker for the malignant progression of leukoplakia. *Journal of Oral Pathology and Medicine*. 46(3); 223-231, 2017.
80. Lam PD, Kuribayashi A, Sakamoto J, Nakamura S, **Harada H**, Kurabayashi T. Imaging findings of childhood B-cell lymphoblastic lymphoma in the mental region: a case report. *Dentomaxillofacial Radiology*. 46(3); 20160313, 2017.
81. Oikawa Y, Morita K, Kayamori K, Tanimoto K, Sakamoto K, Katoh H, Ishikawa S, Inazawa J, **Harada H**. Receptor tyrosine kinase amplification is predictive of distant metastasis in patients with oral squamous cell carcinoma. *Cancer Science*. 108; 256-266, 2017.
82. Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, **Harada H**, Suzuki H, Nishioka Y, Kato Y. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas and TALEN. *Cancer Medicine*. 6(2):382-396,2017.
83. Kaneko MK, Kunita A, Yamada S, Nakamura T, Miyuki Yanaka, Saidoh N, Chang YW, Handa S, Ogasawara S, Ohishi T, Abe S, Itai S, **Harada H**, Kawada M, Nishioka Y, Fukayama M, Kato Y. Anti-Podocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas. *Monoclon. Antib. Immunodiagn. Immunother*. 36(4):157-162, 2017.
84. Mochizuki Y, Tomioka H, Tsushima F, Shimamoto H, HirainH, Oikawa Y, **Harada H**. Clinical evaluation of the coverage of open wounds in oral surgical field with a polyglycolic acid sheet and a fibrin glue spray and coverage with split thickness skin graft. *Annals of Maxillofac Surg* 6(2):228-234, 2016.
85. Nguyen CTK., Okamura T., Morita K., Yamaguchi S., **Harada H**., Miki Y., Izumo T., Kayamori K., Yamaguchi A., Sakamoto K. LAMC2 is a predictive marker for the malignant progression of leukoplakia. *J Oral Pathol Med*. 46(3):223-231, 2016.
86. Abe S., Yamaguchi S., Sato Y., **Harada K**. Sphere-derived multipotent progenitor cells obtained from human oral mucosa are enriched in neural crest cells. *Stem cells*

*translational medicine*. 5:117-128, 2016.

87. Yoshida C., Yamaguchi S., Abe S., **Harada K.**, Property of Human Bone Marrow Stromal Cells Derived From Bone Fragments Removed in Sagittal Split Ramus Osteotomy. *J Craniofac. Surg*. 27(4):1104-1109, 2016.
88. Terauchi M, Inada T, Tonegawa A, Tamura A, Yamaguchi S, **Harada K**, Yui N. Supramolecular inclusion complexation of simvastatin with methylated  $\beta$ -cyclodextrins for promoting osteogenic differentiation. *Int. J. Biol. Macromol.* 12; 93(PtB); 1492-1498, 2016.
89. Morita T, Uzawa N, Mogushi K, Sumino J, Michikawa C, Takahashi K, Myo K, Izumo T, **Harada K**. Characterizing Genetic Transitions of Copy Number Alterations and Allelic Imbalances in Oral Tongue Carcinoma Metastasis. *Genes Chromosomes Cancer*. 12; 55; 975-986, 2016.
90. Wake S, Yoshitake H, Kayamori K, Izumo T, **Harada K**. Expression of CD90 decreases with progression of synovial chondromatosis in the temporomandibular joint. *Cranio*. 34(4); 250-256, 2016.
91. Yoshitake H, Kayamori K, Wake S, Sato F, Kino **K,Harada K**. Synovial chondromatosis of the right side temporomandibular joint extending to the middle cranial fossa: A case report with 7-year postoperative follow up and expression of a biomarker of cell proliferative activity. *Anat Rec (Hoboken)*. 06; 20; 133-137, 2016.
92. Okuyama K, Michi Y, Mizutani M, Yamashiro M, Kaida A, **Harada K**. Clinical study on mandibular fracture after marginal resection of the mandible. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 121(5); 461-467, 2016.
93. Kayamori K, Katsube K, Sakamoto K, Ohyama Y, Hirai H, Yukimori A, Ohata Y, Akashi T, Saitoh M, **Harada K, Harada H**, Yamaguchi A. NOTCH3 Is Induced in Cancer-Associated Fibroblasts and Promotes Angiogenesis in Oral Squamous Cell Carcinoma. *PLoS One*. 11(4); e0154112, 2016.
94. Morita T, Yamashiro M, Kayamori K, Mizutani M, Nakakuki K, Michi Y, Uzawa N, Izumo T, **Harada K**. Primary intraosseous squamous cell carcinoma derived from a maxillary cyst: A case report and literature review. *Mol Clin Oncol*. 4(4); 553-558, 2016.
95. Matsushita Y, Nakakuki K, Kosugi M, Kurohara K, **Harada K**. Does Intraoral miniplate fixation have a good postoperative stability after sagittal splitting ramus osteotomy?: Comparison with intraoral bicortical screw fixation. *Journal of Oral and Maxillofacial Surgery*. 74; 181-189, 2016.
96. Kondo Y, Ohno T, Nishii N, **Harada K**, Yagita H, Azuma M. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to

- antitumor responses against squamous cell carcinoma. *Oral Oncology*. 57; 54-60, 2016.
97. Okamura T, Izumo T, Yagishita H, Mori T, Sakamoto K, **Harada K**. Disorderd arrangements of basal cells as a prognostic factor for oral epithelial dysplasia : a morphometric study of 96 cases. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 122(3):355-361, 2016.
98. Oda S, Nozawa T, Nozawa-Minowa A, Tanaka M, Aikawa C, **Harada H**, Nakagawa I. Golgi-Resident GTPase Rab30 Promotes the Biogenesis of Pathogen-Containing Autophagosomes. *PLoS One*. 11(1):e0147061, 2016.
99. Kohmoto T, Tsuji A, Morita K, Naruto T, Masuda K, Kashimada K, Enomoto K, Morio T, **Harada H**, Imoto I. A novel COL11A1 missense mutation in siblings with non-ocular Stickler syndrome. *Hum Genome Var*. 3:16003, 2016.
100. Kudoh M, Omura K, Satsukawa A, Matsumoto K, Taguchi T, **Harada H**, Ishii Y. Symmetric Lipomatosis Arising in the Tongue Presenting as Macroglossia and Articulatory Disorder. *Case Rep Otolaryngol*. 2016:2061649, 2016.
101. Dilruba Aktar, Tomioka H, Hirai H, Oikawa Y, Mochizuki Y, Shimamoto H and **Harada H**. Value of real-time tissue elastography for squamous cell carcinoma of the tongue. *Dental, Oral and Craniofacial Research* 2(6):371-375, 2016.